Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) jumped on Thursday after the company raised its full-year guidance ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

As of August 28 at 4:00 PM EDT. Market Open. Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and ...

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...